{"id":"octreotide-lar","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Abdominal pain"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Injection site pain"},{"rate":"15-25","effect":"Cholelithiasis (gallstones)"},{"rate":"5-15","effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL1680","moleculeType":"Protein","molecularWeight":"1019.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Octreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells. This suppresses the release of growth hormone, insulin-like growth factor-1 (IGF-1), and other peptide hormones. The LAR (long-acting release) formulation provides sustained therapeutic levels over 4 weeks via intramuscular injection.","oneSentence":"Octreotide LAR is a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone, insulin, and other hormones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:48.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Neuroendocrine tumors (carcinoid syndrome, VIPomas)"},{"name":"Gastroenteropancreatic neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT07255248","phase":"PHASE4","title":"Hoffa's Fat Pad Impingement (HFPI)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-03-01","conditions":"Hoffa's Fat Pad Impingement","enrollment":62},{"nctId":"NCT06784752","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-30","conditions":"Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)","enrollment":240},{"nctId":"NCT03879694","phase":"PHASE1","title":"Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-06-17","conditions":"Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor","enrollment":19},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":226},{"nctId":"NCT05364944","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2022-05-18","conditions":"Acromegaly, GEP-NET","enrollment":19},{"nctId":"NCT05050942","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2021-10-22","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":332},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":"Neuroendocrine Tumors","enrollment":196},{"nctId":"NCT06193616","phase":"","title":"Outcome of ADPKD With Octreotide LAR","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2024-02-12","conditions":"Autosomal Dominant Polycystic Kidney","enrollment":70},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT07057622","phase":"PHASE3","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","status":"RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2023-12-12","conditions":"NETS Ga68 Lu177","enrollment":184},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":"Neuroendocrine Tumors","enrollment":51},{"nctId":"NCT00113360","phase":"PHASE2","title":"RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-01","conditions":"Neuroendocrine Carcinoma, Islet Cell Carcinoma","enrollment":67},{"nctId":"NCT03792555","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2019-03-11","conditions":"Acromegaly","enrollment":13},{"nctId":"NCT02736448","phase":"PHASE2","title":"177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-05","conditions":"Gastro-entero-pancreatic Neuroendocrine Tumors","enrollment":35},{"nctId":"NCT06753630","phase":"NA","title":"Polydeoxyribonucleotide for Elbow Lateral Epicondylitis","status":"COMPLETED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2014-11-20","conditions":"Lateral Epicondylitis, Extracorporeal Shockwave Therapy, Muscle Strengthening","enrollment":48},{"nctId":"NCT04871204","phase":"PHASE2","title":"Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer","status":"COMPLETED","sponsor":"Fredrik Klevebro","startDate":"2021-06-16","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":20},{"nctId":"NCT06505395","phase":"PHASE2","title":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-07-30","conditions":"Gastrointestinal Neuroendocrine Pancreatic Tumor","enrollment":90},{"nctId":"NCT01424241","phase":"PHASE4","title":"Effects of Sandostatin LAR® in Acromegaly","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-10","conditions":"Acromegaly","enrollment":21},{"nctId":"NCT05701241","phase":"PHASE4","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-06-28","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":270},{"nctId":"NCT06080204","phase":"NA","title":"Real-world Study on Adjuvant Octreotide Therapy in pNETs","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2008-03","conditions":"Pancreatic Neuroendocrine Tumor G2","enrollment":411},{"nctId":"NCT05761431","phase":"PHASE1","title":"A Single-dose Study of Octreotide Injection in Healthy Adult Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-03-02","conditions":"Acromegaly","enrollment":56},{"nctId":"NCT00427349","phase":"PHASE2","title":"AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2008-11-07","conditions":"Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome","enrollment":46},{"nctId":"NCT02333565","phase":"PHASE2","title":"Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2015-01-22","conditions":"Recurrent Meningiomas, Resistant Meningiomas","enrollment":20},{"nctId":"NCT02384122","phase":"PHASE3","title":"Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-09","conditions":"Angiodysplasia, Vascular Malformations, Gastrointestinal Hemorrhage","enrollment":62},{"nctId":"NCT01538966","phase":"NA","title":"Acromegaly Combination Treatment Study","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-03-29","conditions":"Acromegaly","enrollment":76},{"nctId":"NCT01613495","phase":"NA","title":"Ghrelin Suppression by Octreotide in Prader-Willi","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2005-08","conditions":"Prader Willis Syndrome","enrollment":2},{"nctId":"NCT01086982","phase":"PHASE1","title":"Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®","status":"SUSPENDED","sponsor":"Azidus Brasil","startDate":"2010-03","conditions":"Acromegaly","enrollment":16},{"nctId":"NCT03541447","phase":"PHASE2","title":"Tolvaptan-Octreotide LAR Combination in ADPKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-12-12","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":20},{"nctId":"NCT01229943","phase":"PHASE2","title":"Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-15","conditions":"Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma","enrollment":150},{"nctId":"NCT01578239","phase":"PHASE3","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2012-09-06","conditions":"Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour","enrollment":231},{"nctId":"NCT02294006","phase":"PHASE2","title":"Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2014-06","conditions":"Well Differentiated Pancreatic Endocrine Tumor","enrollment":26},{"nctId":"NCT01789281","phase":"PHASE4","title":"Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05-14","conditions":"Neoplasms","enrollment":34},{"nctId":"NCT02973204","phase":"","title":"Circulating Tumor Cells and Tumor DNA in HCC and NET","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-11","conditions":"Carcinoma, Hepatocellular, Neuroendocrine Tumors","enrollment":167},{"nctId":"NCT01744249","phase":"PHASE2, PHASE3","title":"Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas","status":"UNKNOWN","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2011-11","conditions":"Neuroendocrine Tumors, Advanced Cancer","enrollment":255},{"nctId":"NCT02916433","phase":"PHASE2","title":"Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients","status":"COMPLETED","sponsor":"Danbury Hospital","startDate":"2016-09","conditions":"Octreotide, Sputum","enrollment":5},{"nctId":"NCT04129255","phase":"PHASE2","title":"Octreotide LAR in the Induction of Immunologic Response in NENs Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2017-06-28","conditions":"Neuroendocrine Tumors","enrollment":34},{"nctId":"NCT00092287","phase":"PHASE3","title":"Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","status":"TERMINATED","sponsor":"Ipsen","startDate":"2004-07","conditions":"Malignant Carcinoid Syndrome","enrollment":4},{"nctId":"NCT00002864","phase":"PHASE3","title":"Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1996-09-24","conditions":"Breast Cancer","enrollment":667},{"nctId":"NCT00171873","phase":"PHASE3","title":"Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut","status":"COMPLETED","sponsor":"Carmen Schade-Brittinger","startDate":"2001-09","conditions":"Neuroendocrine Tumors","enrollment":85},{"nctId":"NCT00444873","phase":"PHASE3","title":"Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly","status":"COMPLETED","sponsor":"Ipsen","startDate":"2005-01","conditions":"Acromegaly","enrollment":38},{"nctId":"NCT04140409","phase":"PHASE4","title":"Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2016-02-02","conditions":"Neuroendocrine Tumors, Carcinoid Syndrome","enrollment":10},{"nctId":"NCT00216398","phase":"PHASE4","title":"Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR","status":"COMPLETED","sponsor":"Ipsen","startDate":"2004-06","conditions":"Acromegaly","enrollment":8},{"nctId":"NCT02294786","phase":"PHASE2","title":"Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-17","conditions":"Cancer","enrollment":62},{"nctId":"NCT03057509","phase":"PHASE1","title":"A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2018-11","conditions":"Small Bowel Carcinoid Tumor","enrollment":""},{"nctId":"NCT02396953","phase":"PHASE1, PHASE2","title":"Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly","status":"COMPLETED","sponsor":"Ipsen","startDate":"2015-03","conditions":"Acromegaly","enrollment":28},{"nctId":"NCT00701363","phase":"PHASE4","title":"Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects","status":"COMPLETED","sponsor":"Ipsen","startDate":"2008-10","conditions":"Acromegaly","enrollment":124},{"nctId":"NCT00853047","phase":"PHASE2","title":"Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2009-03","conditions":"Carcinoid Syndrome","enrollment":23},{"nctId":"NCT03017690","phase":"","title":"Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2017-04-12","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":22},{"nctId":"NCT00552071","phase":"PHASE4","title":"Ultrasound Guided Octreotide LAR Injection in Acromegaly","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2007-07","conditions":"Acromegaly","enrollment":15},{"nctId":"NCT02874326","phase":"PHASE2","title":"Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-10","conditions":"Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia","enrollment":15},{"nctId":"NCT01137682","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07-19","conditions":"Acromegaly","enrollment":198},{"nctId":"NCT02021942","phase":"PHASE2","title":"Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size","status":"COMPLETED","sponsor":"Prof. Dr. Berthold Schalke","startDate":"2012-03","conditions":"Primary Inoperable Thymoma, Local Recurrent Thymoma","enrollment":16},{"nctId":"NCT01377246","phase":"PHASE3","title":"Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2011-05","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":100},{"nctId":"NCT01567488","phase":"PHASE2","title":"Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET","status":"COMPLETED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2011-06-08","conditions":"Gastrointestinal Neoplasms","enrollment":43},{"nctId":"NCT02299089","phase":"PHASE2","title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2015-01","conditions":"Acromegaly, Neuroendocrine Tumors","enrollment":12},{"nctId":"NCT00600886","phase":"PHASE3","title":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-02-11","conditions":"Acromegaly","enrollment":358},{"nctId":"NCT01278342","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Acromegaly","enrollment":70},{"nctId":"NCT01707225","phase":"PHASE1","title":"Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2013-02","conditions":"Gastrointestinal Bleeding","enrollment":10},{"nctId":"NCT01618513","phase":"PHASE4","title":"Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-06","conditions":"Acromegaly","enrollment":84},{"nctId":"NCT01371643","phase":"PHASE4","title":"Surgical Debulking of Pituitary Adenomas","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2004-04","conditions":"Pituitary Adenoma","enrollment":41},{"nctId":"NCT02668172","phase":"PHASE4","title":"Pasireotide LAR and Pegvisomant Study in Acromegaly","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-08","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT01204476","phase":"PHASE1","title":"Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10","conditions":"Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1","enrollment":27},{"nctId":"NCT01121939","phase":"PHASE2","title":"Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-05","conditions":"Neuroendocrine Carcinoma","enrollment":43},{"nctId":"NCT02631616","phase":"PHASE1","title":"Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2016-02","conditions":"Prostatic Neoplasms","enrollment":30},{"nctId":"NCT00075868","phase":"PHASE3","title":"Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2003-12","conditions":"Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ","enrollment":233},{"nctId":"NCT01157858","phase":"PHASE2","title":"Everolimus and LongActing Octreotide Trial in Polycystic Livers","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-06","conditions":"Polycystic Liver Disease","enrollment":44},{"nctId":"NCT01480986","phase":"PHASE2","title":"IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC","status":"COMPLETED","sponsor":"Peking University","startDate":"2011-09","conditions":"Progression Free Survival of the Treatment","enrollment":40},{"nctId":"NCT00582426","phase":"PHASE3","title":"Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Chemotherapy-induced Diarrhea","enrollment":139},{"nctId":"NCT02427295","phase":"PHASE4","title":"Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-03","conditions":"Acromegaly","enrollment":1},{"nctId":"NCT02409849","phase":"PHASE2","title":"Octreotide LAR as Maintenance Treatment for Patients With NEC","status":"UNKNOWN","sponsor":"Peking University","startDate":"2015-04","conditions":"Gastro-entero-pancreatic Carcinoma, Esophageal Neuroendocrine Carcinoma","enrollment":92},{"nctId":"NCT01886287","phase":"PHASE2","title":"P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-12","conditions":"Neuroendocrine Carcinoma","enrollment":2},{"nctId":"NCT01469338","phase":"PHASE2","title":"Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2012-07","conditions":"Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer","enrollment":9},{"nctId":"NCT00412061","phase":"PHASE3","title":"Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Carcinoid Tumor, Malignant Carcinoid Syndrome","enrollment":429},{"nctId":"NCT00521300","phase":"PHASE4","title":"Preoperative Octreotide Treatment of Acromegaly","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"1999-09","conditions":"Acromegaly","enrollment":62},{"nctId":"NCT00108355","phase":"PHASE4","title":"Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2003-12","conditions":"Ascites, Cirrhosis","enrollment":29},{"nctId":"NCT00510224","phase":"PHASE2","title":"Sandostatin for Patients With Androgen Independent Prostate Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2007-07","conditions":"Prostate Cancer","enrollment":13},{"nctId":"NCT00765323","phase":"PHASE3","title":"Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly","status":"TERMINATED","sponsor":"Endo Pharmaceuticals","startDate":"2008-09","conditions":"Acromegaly","enrollment":169},{"nctId":"NCT00690430","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Symptomatic Refractory Resistant Carcinoid Disease","enrollment":186},{"nctId":"NCT00002967","phase":"PHASE3","title":"Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"1997-05","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00309283","phase":"PHASE3","title":"Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2006-04","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":78},{"nctId":"NCT00426153","phase":"PHASE2, PHASE3","title":"Octreotide in Severe Polycystic Liver Disease","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly","enrollment":42},{"nctId":"NCT00006269","phase":"PHASE3","title":"Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer","status":"TERMINATED","sponsor":"Novartis","startDate":"1999-12","conditions":"Colorectal Cancer, Diarrhea","enrollment":89},{"nctId":"NCT00128232","phase":"PHASE3","title":"Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-12","conditions":"Acromegaly","enrollment":100},{"nctId":"NCT00225979","phase":"PHASE3","title":"Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-11","conditions":"Acromegaly","enrollment":100},{"nctId":"NCT00332696","phase":"PHASE2","title":"Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis","enrollment":64},{"nctId":"NCT00076362","phase":"PHASE4","title":"Pediatric Hypothalamic Obesity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-03","conditions":"Obesity","enrollment":60},{"nctId":"NCT00913055","phase":"PHASE2","title":"Open Label Study of Octreotide Implant in Patients With Acromegaly","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2007-02","conditions":"Acromegaly","enrollment":34},{"nctId":"NCT00590343","phase":"PHASE2","title":"Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2004-11","conditions":"Metastatic Neuroendocrine Tumors","enrollment":23},{"nctId":"NCT00372697","phase":"PHASE3","title":"Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Acromegaly","enrollment":28},{"nctId":"NCT00789841","phase":"","title":"Gastrointestinal Motility in Patients With Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2008-09","conditions":"Neuroendocrine Tumor","enrollment":13},{"nctId":"NCT01203306","phase":"PHASE2","title":"Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2006-01","conditions":"Neuroendocrine Carcinomas","enrollment":42},{"nctId":"NCT01188733","phase":"PHASE1, PHASE2","title":"Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"1998-06","conditions":"Cirrhosis, Portal Hypertension, Esophageal Varices","enrollment":39},{"nctId":"NCT00642421","phase":"PHASE3","title":"Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients","status":"TERMINATED","sponsor":"Ambrilia Biopharma, Inc.","startDate":"2008-02","conditions":"Acromegaly","enrollment":40},{"nctId":"NCT00250796","phase":"PHASE2","title":"Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2000-09","conditions":"Liver, Cancer","enrollment":12},{"nctId":"NCT00166725","phase":"PHASE2","title":"Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-02","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT00050635","phase":"PHASE4","title":"STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-12","conditions":"Neoplasms, Diarrhea","enrollment":150},{"nctId":"NCT00990535","phase":"PHASE2","title":"High Dose Somatostatin Analogues in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Federico II University","startDate":"2006-01","conditions":"Respiratory Tract Neoplasms, Thymic Neoplasms, Pancreatic Neoplasms","enrollment":28},{"nctId":"NCT00094146","phase":"PHASE2","title":"Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-01","conditions":"Primary Insulin Hypersecretion, Obesity","enrollment":160}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":3,"reaction":"PAIN"},{"count":3,"reaction":"PITUITARY TUMOUR BENIGN"},{"count":3,"reaction":"WEIGHT DECREASED"},{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"ANOREXIA"},{"count":2,"reaction":"ASCITES"},{"count":2,"reaction":"DEATH"},{"count":2,"reaction":"DISEASE PROGRESSION"},{"count":2,"reaction":"DRUG INEFFECTIVE"}],"_approvalHistory":[],"publicationCount":484,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sandostatin","Sandostatin LAR®","Sandostatin® LAR","SOM230","SANDOSTATIN LAR, Octreotide"],"phase":"marketed","status":"active","brandName":"Octreotide LAR","genericName":"Octreotide LAR","companyName":"Cedars-Sinai Medical Center","companyId":"cedars-sinai-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Octreotide LAR is a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone, insulin, and other hormones. Used for Acromegaly, Carcinoid syndrome, Variceal bleeding in portal hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}